Is GLOPERBA® (colchicine) right for your patients with gout?

GLOPERBA is the first and only liquid colchicine

Simplified dose adjustment allows you to individualize therapy, patient to patient

Oral syringe
  • GLOPERBA is indicated for the prophylaxis of gout flares in adults1
  • Unique liquid oral solution1,2
  • Allows for simple and precise titration when necessary
  • Pleasant cherry taste
GLOPERBA brings flexibility to the management of chronic gout with colchicine

GLOPERBA delivers the proven efficacy of colchicine

Colchicine prophylaxis* + urate-lowering therapy significantly reduces the frequency of gout flares vs urate-lowering therapy alone3

Patients taking allopurinol plus colchicine had 0.52 flares between 0-6 months, while patients taking allopurinol plus placebo had 2.91 flares between 0-6 months. 82% reduction in gout flares at month 6.
Patients taking allopurinol plus colchicine had 0.52 flares between 0-6 months, while patients taking allopurinol plus placebo had 2.91 flares between 0-6 months. 82% reduction in gout flares at month 6.

Study Design Randomized, prospective, double-blind, placebo-controlled trial evaluating the safety and efficacy of colchicine in the management of gout (N=43). Patients starting allopurinol were randomized to receive colchicine 0.6 mg twice a day or placebo. Average baseline serum urate levels were 9.49 mg/dL in the colchicine group.3

GLOPERBA is an approved NDA based on the demonstrated bioequivalence of a 0.6-mg colchicine tablet with 5 mL (0.6 mg) of GLOPERBA solution. The efficacy data presented here are from the study of 0.6 mg of colchicine for the prophylaxis of gout flares.

Harness the power of colchicine to control inflammation and prevent gout flares with GLOPERBA

As a liquid, GLOPERBA was designed for the real-world gout patient, who is likely to have comorbidities

Patients who have gout may require colchicine titration, especially those with kidney and liver problems

NHANES: Common comorbidities in patients with gout4

NHANES: common comorbidites in patients with gout include diabetes mellitus (26%), congestive heart failure (33%), obestiy (53%), Renal impairment (71%), and hypertention (74%).
NHANES: common comorbidites in patients with gout include diabetes mellitus (26%), congestive heart failure (33%), obestiy (53%), Renal impairment (71%), and hypertention (74%).

Estimated prevalence of major comorbidities associated with gout using data from 5707 participants aged 20 years or older in the National Health and Nutrition Examination Survey (NHANES) 2007-2008.4

The typical gout patient requires an individualized dose of colchicine for inflammation prophylaxis4

GLOPERBA was designed for easy administration and dose titration1

In clinical trials, gout-flare prophylaxis with colchicine was administered for a 6-month period3

  • Recommended dose of GLOPERBA is 0.6 mg (5 mL) once or twice daily1
  • Maximum dose is 1.2 mg daily1
  • Dose modifications or adjustments should be considered in patients with renal dysfunction or hepatic impairment1
  • GLOPERBA can be taken with or without food1
  • Dosing syringe facilitates precise dosing by patients based on your directions
Colchicine 0.1 mg to GLOPERBA 0.83 mL. Colchicine 0.2 mg to GLOPERBA 1.67 mL. Colchicine 0.3 mg to GLOPERBA 2.5 mL. Colchicine 0.4 mg to GLOPERBA 3.33 mL. Colchicine 0.5 mg to GLOPERBA 4.17 mL. Colchicine 0.6 mg to GLOPERBA 5.0 mL. Colchicine 0.7 mg to GLOPERBA 5.83 mL. Colchicine 0.8 mg to GLOPERBA 6.67 mL. Colchicine 0.9 mg to GLOPERBA 7.5 mL. Colchicine 1.0 mg to GLOPERBA 8.33 mL. Colchicine 1.1 mg to GLOPERBA 9.17 mL. Colchicine 1.2 mg to GLOPERBA 10.0 mL.
Colchicine 0.1 mg to GLOPERBA 0.83 mL. Colchicine 0.2 mg to GLOPERBA 1.67 mL. Colchicine 0.3 mg to GLOPERBA 2.5 mL. Colchicine 0.4 mg to GLOPERBA 3.33 mL. Colchicine 0.5 mg to GLOPERBA 4.17 mL. Colchicine 0.6 mg to GLOPERBA 5.0 mL. Colchicine 0.7 mg to GLOPERBA 5.83 mL. Colchicine 0.8 mg to GLOPERBA 6.67 mL. Colchicine 0.9 mg to GLOPERBA 7.5 mL. Colchicine 1.0 mg to GLOPERBA 8.33 mL. Colchicine 1.1 mg to GLOPERBA 9.17 mL. Colchicine 1.2 mg to GLOPERBA 10.0 mL.
With a liquid formulation, you have the ability to precisely tailor dosing in gout patients with comorbidities

The safety profile of colchicine is well characterized

The use of colchicine in the management of chronic gout has been studied for decades5

The safety of colchicine as a part of gout-flare prophylaxis was established in 2 randomized, placebo-controlled trials1

The safety of colchicine is backed by decades of real-world clinical experience5

The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.1